Histological Efficacy Confirmed in Phase 2a Trial

TEV-53408 (TEV '408), an investigational human monoclonal antibody under development by Teva Pharmaceutical Industries Ltd. (TEVA) that inhibits interleukin-15 (IL-15), showed promising results in a randomized, placebo-controlled Phase 2a study (NCT06807463). The trial enrolled 50 adult celiac disease patients on a gluten-free diet, who received a single subcutaneous dose followed by a six-week gluten challenge. At week 8, the least squares mean change in villus height to crypt depth ratio (Vh:Cd) was -0.43 in the TEV-53408 group versus -0.88 in the placebo group, yielding a treatment difference of 0.45 (95% CI 0.06–0.84; p < 0.05). This primary endpoint, based on biopsy measurements of intestinal mucosal damage, carries greater clinical weight than symptom improvement alone.

IL-15 Blockade Mechanism and Safety

Changes in intraepithelial lymphocyte (IEL) density were 0.37 in the TEV-53408 group versus 27.60 in the placebo group, with a treatment difference of -27.23 (95% CI -39.67 to -14.79). Given that IL-15 activates cytotoxic lymphocytes and amplifies gluten-induced epithelial damage in celiac disease, this result provides pharmacodynamic evidence that TEV-53408 blocks the inflammatory pathway. Gastrointestinal symptoms, as assessed by the Celiac Disease Symptom Diary, were also lower in the TEV-53408 group, with no new safety signals and good tolerability observed. However, the small sample size and single-dose, gluten-challenge design highlight the need for further studies to assess long-term efficacy and infection risk with repeated dosing.

Competitive Landscape Targeting an Approval Gap

The standard of care for celiac disease in the U.S. remains a strict gluten-free diet, with no FDA-approved drugs available. TEV-53408 addresses a clear unmet need as a dietary supplement. A direct IL-15 competitor, ordesekimab (AMG 714/PRV-015), failed to meet its primary endpoint in Phase 2b, underscoring the significance of the histological efficacy demonstrated by TEV-53408. Another key competitor with a different mechanism is Takeda Pharmaceutical Company (TAK)'s oral tissue transglutaminase-2 (TG2) inhibitor ZED1227/TAK-227, which is in Phase 2b. The gluten-degrading enzyme latiglutenase (IMGX-003/ALV003) has completed Phase 2, but inconsistent efficacy across studies remains a key competitive factor.

Regulatory, Market, and Valuation Implications

The FDA granted Fast Track designation to TEV-53408 for celiac disease in May 2025. This announcement reflects a positive top-line result from Phase 2a, not a regulatory approval or advisory committee decision. Grand View Research forecasts the global celiac disease treatment market to reach USD 769.3 million in 2025, USD 851.9 million in 2026, and USD 1.84 billion by 2033, with an annual growth rate of 11.6%. TEV-53408 is also being developed for vitiligo, making it a pipeline-in-a-product asset with potential for multiple indications. For Teva, it represents an innovative biopharma candidate to reduce generic dependency, though the next valuation milestone will be replicating histological efficacy, symptom improvement, and safety in large-scale late-stage trials.